<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02131506</url>
  </required_header>
  <id_info>
    <org_study_id>IRST174.01</org_study_id>
    <secondary_id>2009-012996-82</secondary_id>
    <nct_id>NCT02131506</nct_id>
  </id_info>
  <brief_title>A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer</brief_title>
  <acronym>CAELYX</acronym>
  <official_title>A Phase Ib Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ib Study of Lapatinib in Combination with Caelyx in Patients with Advanced HER2
      positive pretreated Breast Cancer.

      Treatment Plan:

      Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is
      administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined
      as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq &amp; Lapatinib 1000 mg
      die; dose level 1, Caelyx 30 mg/mq &amp; Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq &amp;
      Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq &amp; Lapatinib 1500 mg die. Three patients
      will be initially enrolled in each dose level starting from level 1. If none of the first
      triplet of patients will develop DLT, the dose will be escalated to the next level for the
      subsequent three patients. If one of the first triplets of patients will develop first-course
      DLT, a maximum of 3 additional patients will be entered at the same dose level. The MTD is
      defined as the dose below that at which two patients have experienced DLT. Lapatinib will be
      self-administered by the patient in an outpatient setting at the dose of the assigned step.
      Patients will take the drug daily by mouth on days 1 to 21 of each cycle. Caelyx will be
      administered by intravenous infusion over an exact period of 1 hour (preferably by a pump to
      guarantee a constant speed of infusion) on day

      1 of each cycle repeated every 21 days.

      STATISTICAL METHODOLOGY:

      Evaluation of toxicity: all patients will be evaluable for toxicity from the time of their
      first treatment with Caelyx and Lapatinib.

      Evaluation of response: all patients included in the study must be assessed for response to
      treatment, even if there are major protocol treatment deviations or if they are ineligible.

      All conclusions should be based on all eligible patients. Subanalyses may then be performed
      on the basis of a subset of patients, excluding those for whom major protocol deviations have
      been identified .However, these subanalyses may not serve as the basis for drawing
      conclusions concerning treatment efficacy, and the reasons for excluding patients from the
      analysis should be clearly reported. The 95% confidence intervals should also be provided.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Title: A Phase Ib Study of Lapatinib in Combination with Caelyx in Patients with Advanced
      HER2 positive pretreated Breast Cancer. Protocol Code: IRST 174.01 Phase: Ib Study Design:
      open-label,single arm study in patients with advanced HER2 positive breast cancer.

      Treatment Plan:

      Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is
      administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined
      as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq &amp; Lapatinib 1000 mg
      die; dose level 1, Caelyx 30 mg/mq &amp; Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq &amp;
      Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq &amp; Lapatinib 1500 mg die. Three patients
      will be initially enrolled in each dose level starting from level 1. If none of the first
      triplet of patients will develop DLT, the dose will be escalated to the next level for the
      subsequent three patients. If one of the first triplets of patients will develop first-course
      DLT, a maximum of 3 additional patients will be entered at the same dose level. The MTD is
      defined as the dose below that at which two patients have experienced DLT. Lapatinib will be
      self-administered by the patient in an outpatient setting at the dose of the assigned step.
      Patients will take the drug daily by mouth on days 1 to 21 of each cycle. Caelyx will be
      administered by intravenous infusion over an exact period of 1 hour (preferably by a pump to
      guarantee a constant speed of infusion) on day

      1 of each cycle repeated every 21 days.

      Objectives:

      Primary: to define the MTD and the safety profile of Lapatinib (Tyverb) plus Caelyx.
      Secondary: to preliminarily explore the anti tumour activity, to determine the objective
      tumor response rate using RECIST criteria.

      Sample Size:

      No formal sample size estimation is performed as this is primarily a descriptive phase I
      trial of safety and tolerability.

      STATISTICAL METHODOLOGY:

      Evaluation of toxicity: all patients will be evaluable for toxicity from the time of their
      first treatment with Caelyx and Lapatinib. Evaluation of response: all patients included in
      the study must be assessed for response to treatment, even if there are major protocol
      treatment deviations or if they are ineligible. Each patient will be assigned one of the
      following categories: 1) complete response, 2) partial response, 3) stable disease, 4)
      progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7)
      early death because of other cause, or 9) unknown (not assessable, insufficient data). All of
      the patients who met the eligibility criteria (with the possible exception of those who
      received no study medication) should be included in the main analysis of the response rate.
      Patients in response categories 4-9 should be considered as failing to respond to treatment
      (PD). Thus, an incorrect treatment schedule or drug administration does not result in
      exclusion from the analysis of the response rate.

      All conclusions should be based on all eligible patients. Subanalyses may then be performed
      on the basis of a subset of patients, excluding those for whom major protocol deviations have
      been identified (e.g., early death due to other reasons, early discontinuation of treatment,
      major protocol violations, etc.). However, these subanalyses may not serve as the basis for
      drawing conclusions concerning treatment efficacy, and the reasons for excluding patients
      from the analysis should be clearly reported. The 95% confidence intervals should also be
      provided.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety reasons
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD (Maximum Tolerated Dose)</measure>
    <time_frame>6 years</time_frame>
    <description>The MTD (Maximum Tolerated Dose) is defined as the dose below that at which two patients have experienced DLT (Dose Limiting Toxicity).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti tumour activity of Lapatinib in combination with Caelyx in terms of Objective Response Rate (CR or PR).</measure>
    <time_frame>6 years</time_frame>
    <description>Response and progression are evaluated using the RECIST Criteria (Response Evaluation Criteria In Solid Tumors).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of toxicity.</measure>
    <time_frame>6 years.</time_frame>
    <description>All patients will be evaluable for toxicity from the time of their first treatment with Caelyx and Lapatinib, using NCI-CTCAE v.3 (National cancer Institute - Common Terminology Criteria for Adverse Events).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>HER-2 Positive Breast Cancer</condition>
  <condition>Malignant Neoplasm of Breast</condition>
  <arm_group>
    <arm_group_label>Lapatinib, Caelyx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lapatinib is given at escalating doses orally and continuously on days 1-21.
Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib, Caelyx</intervention_name>
    <description>Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq &amp; Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq &amp; Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq &amp; Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq &amp; Lapatinib 1500 mg die</description>
    <arm_group_label>Lapatinib, Caelyx</arm_group_label>
    <other_name>Lapatinib</other_name>
    <other_name>Caelyx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with histologically or cytologically confirmed diagnosis of breast
             cancer.

          -  Locally advanced (Stage IIIb or Stage IIIc with T4 lesion) or metastatic (Stage IV)
             disease.

          -  Subjects must have tumors that overexpress ErbB2 defined as +3 by IHC or FISH positive
             for ErbB2 gene amplification. The status of ErbB2 expression must be documented prior
             to study entry.

          -  Subjects must have disease progression (by RECIST) following prior therapy with taxane
             and trastuzumab-containing regimens (if not contraindicated).

          -  Patients may have had any number of prior chemotherapy, immunotherapy, hormonal
             therapy, investigational or radiotherapy regimens, but therapy must be discontinued at
             least 4 weeks before study entry (6 weeks if the last regimen included BCNU or
             mitomycin C).

          -  Age &gt;18 years.

          -  Life expectancy of greater than 12 weeks.

          -  ECOG performance status &lt;2 (see Appendix A).

          -  Cardiac ejection fraction within the institutional range of normal as measured by
             echocardiogram (ECHO).

          -  Previous anthracycline use inferior of 360 mg/mq for epirubicin and 200 mg/mq for
             doxorubicin (provided that patients have been off-treatment for at least one year and
             did not progress under treatment).

          -  Patients must have normal organ and marrow function as defined below:

               -  leukocytes &gt;3,000/mL

               -  absolute neutrophil count &gt;1,500/mL

               -  platelets &gt;100,000/mL

               -  total bilirubin &lt; 1.5 X institutional upper limit of normal

               -  AST(SGOT)/ALT(SGPT) &lt;2.5 X institutional upper limit of normal (â‰¤ 5 in patients
                  with liver metastases)

               -  creatinine &lt; 1.5 X institutional upper limit of normal

          -  Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately.

          -  Ability to swallow and retain oral medications.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Participation in another clinical trial with any investigational agents within 30 days
             prior to study screening.

          -  Prior treatment with Caelyx or Lapatinib.

          -  Previous malignancy except cervical carcinoma in situ, adequately treated basal cell
             carcinoma, superficial bladder tumors, or other malignancies curatively treated &gt; 3
             years before study entry.

          -  Patients with symptomatic brain metastases should be excluded from this clinical trial
             because of their poor prognosis and because they often develop progressive neurologic
             dysfunction, that would confound the evaluation of neurologic and other adverse
             events. Asymptomatic patients are allowed.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Caelyx and Lapatinib or other agents used in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Have current active hepatic or biliary disease (with exception of patients with
             Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver
             disease per investigator assessment);

          -  Malabsorption syndrome or any disease significantly affecting gastrointestinal
             function.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dino Amadori, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRST IRCCS, Meldola</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UO Oncologia medica, IRCCS IRST</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2014</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced HER2 positive Breast Cancer</keyword>
  <keyword>pretreated breast cancer</keyword>
  <keyword>advanced disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

